HRP20160236T1 - Aromatski heterociklički spoj koji sadrži dušik - Google Patents
Aromatski heterociklički spoj koji sadrži dušik Download PDFInfo
- Publication number
- HRP20160236T1 HRP20160236T1 HRP20160236TT HRP20160236T HRP20160236T1 HR P20160236 T1 HRP20160236 T1 HR P20160236T1 HR P20160236T T HRP20160236T T HR P20160236TT HR P20160236 T HRP20160236 T HR P20160236T HR P20160236 T1 HRP20160236 T1 HR P20160236T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- alkyl
- substituents
- compound according
- suitable salt
- Prior art date
Links
- -1 Nitrogen-containing aromatic heterocyclyl compound Chemical class 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 31
- 125000005843 halogen group Chemical group 0.000 claims 24
- 125000001153 fluoro group Chemical group F* 0.000 claims 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 16
- 125000001309 chloro group Chemical group Cl* 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 12
- 238000011321 prophylaxis Methods 0.000 claims 12
- 238000011282 treatment Methods 0.000 claims 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 6
- 230000005856 abnormality Effects 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 230000037356 lipid metabolism Effects 0.000 claims 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- HTEAHSZSRGPJOI-UHFFFAOYSA-N 1-ethyl-4-[3-[4-ethyl-3-(4-hydroxyphenyl)-1,2-oxazol-5-yl]propanoylamino]pyrrole-3-carboxylic acid Chemical compound O1N=C(C=2C=CC(O)=CC=2)C(CC)=C1CCC(=O)NC1=CN(CC)C=C1C(O)=O HTEAHSZSRGPJOI-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- GHVBIHOIQWBOBO-UHFFFAOYSA-N 1-ethyl-4-[3-[2-(4-hydroxyphenyl)-1,3-thiazol-5-yl]propanoylamino]pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CN(CC)C=C1NC(=O)CCC1=CN=C(C=2C=CC(O)=CC=2)S1 GHVBIHOIQWBOBO-UHFFFAOYSA-N 0.000 claims 1
- GFNIVBLMUCUIAH-UHFFFAOYSA-N 1-ethyl-4-[[2-fluoro-3-[2-(4-hydroxyphenyl)-1,3-thiazol-5-yl]propanoyl]amino]pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CN(CC)C=C1NC(=O)C(F)CC1=CN=C(C=2C=CC(O)=CC=2)S1 GFNIVBLMUCUIAH-UHFFFAOYSA-N 0.000 claims 1
- ALVVLQHXAYEATA-UHFFFAOYSA-N 1-ethyl-4-[[2-fluoro-3-[3-(4-hydroxyphenyl)-1,2-oxazol-5-yl]propanoyl]amino]pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CN(CC)C=C1NC(=O)C(F)CC1=CC(C=2C=CC(O)=CC=2)=NO1 ALVVLQHXAYEATA-UHFFFAOYSA-N 0.000 claims 1
- AVEILQAAHGMLPI-UHFFFAOYSA-N 1-ethyl-4-[[3-[4-ethyl-3-(4-hydroxyphenyl)-1,2-oxazol-5-yl]-2,2-difluoropropanoyl]amino]pyrrole-3-carboxylic acid Chemical compound O1N=C(C=2C=CC(O)=CC=2)C(CC)=C1CC(F)(F)C(=O)NC1=CN(CC)C=C1C(O)=O AVEILQAAHGMLPI-UHFFFAOYSA-N 0.000 claims 1
- CEUJNWGDDWADJU-UHFFFAOYSA-N 1-ethyl-4-[[3-[4-ethyl-5-(4-hydroxyphenyl)-1,2-oxazol-3-yl]-2,2-difluoropropanoyl]amino]pyrrole-3-carboxylic acid Chemical compound N=1OC(C=2C=CC(O)=CC=2)=C(CC)C=1CC(F)(F)C(=O)NC1=CN(CC)C=C1C(O)=O CEUJNWGDDWADJU-UHFFFAOYSA-N 0.000 claims 1
- WYHYNZYJRLPPFR-UHFFFAOYSA-N 4-[3-[4-chloro-3-(4-hydroxyphenyl)-1,2-oxazol-5-yl]propanoylamino]-1-ethylpyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CN(CC)C=C1NC(=O)CCC1=C(Cl)C(C=2C=CC(O)=CC=2)=NO1 WYHYNZYJRLPPFR-UHFFFAOYSA-N 0.000 claims 1
- VAIYFXXBAASFBS-UHFFFAOYSA-N 4-[[2,2-difluoro-3-[2-(4-hydroxyphenyl)-1,3-thiazol-5-yl]propanoyl]amino]-1-ethylpyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CN(CC)C=C1NC(=O)C(F)(F)CC1=CN=C(C=2C=CC(O)=CC=2)S1 VAIYFXXBAASFBS-UHFFFAOYSA-N 0.000 claims 1
- NSMSTUZWTFTLNX-UHFFFAOYSA-N 4-[[2,2-difluoro-3-[3-(4-hydroxyphenyl)-1,2-oxazol-5-yl]propanoyl]amino]-1-ethylpyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CN(CC)C=C1NC(=O)C(F)(F)CC1=CC(C=2C=CC(O)=CC=2)=NO1 NSMSTUZWTFTLNX-UHFFFAOYSA-N 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Claims (35)
1. Spoj predstavljen sljedećom općom formulom (I) ili njegova farmakološki prikladna sol
[image]
gdje A uključujući X predstavlja pirolil skupinu, i X predstavlja atom ugljika; ili A uključujući X predstavlja pirazolil skupinu,
R1 predstavlja karboksi skupinu, karboksimetil skupinu, ili tetrazolil skupinu,
svaki R2 nezavisno predstavlja skupinu izabranu iz grupe supstituenata α,
svaki R3 nezavisno predstavlja fenil skupinu, supstituiranu fenil skupinu gdje supstituent(i) predstavlja 1 do 4 skupine nezavisno izabrane iz grupe supstituenata α, 5- ili 6-eročlanu aromatsku heterocikličku skupinu, supstituiranu 5- ili 6-eročlanu aromatsku heterocikličku skupinu gdje supstituent(i) predstavlja 1 do 4 skupine nezavisno izabrane iz grupe supstituenata α, fenil (C1-C6 alkil) skupinu, supstituiranu fenil (C1-C6 alkil) skupinu gdje supstituent(i) predstavlja 1 do 4 skupine nezavisno izabrane iz grupe supstituenata α, 5- ili 6-eročlanu aromatsku heterocikličku(C1-C6 alkil) skupinu, ili supstituiranu 5- ili 6-eročlanu aromatsku heterocikličku(C1-C6 alkil) skupinu gdje supstituent(i) predstavlja 1 do 4 skupine nezavisno izabrane iz grupe supstituenata α,
m predstavlja 0, 1, 2, ili 3,
n predstavlja 0 ili 1, uz uvjet da kada je m 3, n je 0,
svaki od R4, R5, R6 i R7 nezavisno predstavlja atom vodika, C1-C6 alkil skupinu, halogeno(C1-C6 alkil) skupinu, hidroksi skupinu, C1-C6 alkoksi skupinu, ili halogeno skupinu,
B predstavlja naftil skupinu, supstituiranu naftil skupinu gdje supstituent(i) predstavlja 1 do 4 skupine nezavisno izabrane iz grupe supstituenata α, 9- ili 10-eročlanu aromatsku heterocikličku skupinu, supstituiranu 9- ili 10-eročlanu aromatsku heterocikličku skupinu gdje supstituent(i) predstavlja 1 do 4 skupine nezavisno izabrane iz grupe supstituenata α, ili skupinu predstavljenu sljedećom formulom (II)
[image]
gdje svaki od B1 i B2 nezavisno predstavlja fenil skupinu, supstituiranu fenil skupinu gdje supstituent(i) predstavlja 1 do 4 skupine nezavisno izabrane iz grupe supstituenata α, 5- ili 6-eročlanu aromatsku heterocikličku skupinu, ili supstituiranu 5- ili 6-eročlanu aromatsku heterocikličku skupinu gdje supstituent(i) predstavlja 1 do 4 skupine nezavisno izabrane iz grupe supstituenata α, i
grupa supstituenata α predstavlja grupu koju čine C1-C6 alkil skupina, hidroksi(C1-C6 alkil) skupina, (C1-C6 alkoksi)-( C1-C6 alkil) skupina, halogeno(C1-C6 alkil) skupina, (C3-C8 cikloalkil)-(C1-C6 alkil) skupina, C3-C8 cikloalkil skupina, C2-C6 alkenil skupina, C2-C6 alkinil skupina, hidroksi skupina, C1-C6 alkoksi skupina, halogeno(C1-C6 alkoksi) skupina, C1-C6 alkiltio skupina, C1-C6 alkilsulfinil skupina, C1-C6 alkilsulfonil skupina, amino skupina, C1-C6 alkilamino skupina, di(C1-C6 alkil)amino skupina, formilamino skupina, (C1-C6 alkil)karbonilamino skupina, (C1-C6 alkoksi)karbonilamino skupina, (C1-C6 alkil)sulfonilamino skupina, formil skupina, (C1-C6 alkil)karbonil skupina, karboksi skupina, (C1-C6 alkoksi)karbonil skupina, karbamoil skupina, (C1-C6 alkilamino)karbonil skupina, di(C1-C6 alkil)aminokarbonil skupina, aminosulfonil skupina, (C1-C6 alkilamino)sulfonil skupina, di(C1-C6 alkil)aminosulfonil skupina, cijano skupina, nitro skupina, i halogeno skupina.
2. Spoj prema zahtjevu 1 ili njegova farmakološki prikladna sol, koji je predstavljen sljedećom općom formulom (I-1)
[image]
3. Spoj prema zahtjevu 1 ili njegova farmakološki prikladna sol, koji je predstavljen sljedećom općom formulom (I-3):
[image]
gdje R8a predstavlja atom vodika, C1-C6 alkil skupinu, hidroksi(C1-C6 alkil) skupinu, (C1-C6 alkoksi)-(C1-C6 alkil) skupinu, halogeno(C1-C6 alkil) skupinu, (C3-C8 cikloalkil)-(C1-C6 alkil) skupinu, C3-C8 cikloalkil skupinu, C2-C6 alkenil skupinu, C2-C6 alkinil skupinu, C1-C6 alkilsulfonil skupinu, formil skupinu, (C1-C6 alkil)karbonil skupinu, (C1-C6 alkoksi)karbonil skupinu, karbamoil skupinu, (C1-C6 alkilamino)karbonil skupinu, di(C1-C6 alkil)aminokarbonil skupinu, aminosulfonil skupinu, (C1-C6 alkilamino)sulfonil skupinu, ili di(C1-C6 alkil)aminosulfonil skupinu,
svaki R2a nezavisno predstavlja C1-C4 alkil skupinu, halogeno(C1-C4 alkil) skupinu, (C3-C6 cikloalkil)-(C1-C4 alkil) skupinu, C3-C6 cikloalkil skupinu, C2-C4 alkenil skupinu, C2-C4 alkinil skupinu, hidroksi skupinu, C1-C4 alkoksi skupinu, formil skupinu, (C1-C4 alkil)karbonil skupinu, cijano skupinu, ili halogeno skupinu, i
k predstavlja 0, 1, ili 2.
4. Spoj prema zahtjevu 3 ili njegova farmakološki prikladna sol, gdje
R8a predstavlja atom vodika, C1-C4 alkil skupinu, (C1-C2 alkoksi)-(C1-C4 alkil) skupinu, (C3-C6 cikloalkil)-(C1-C4 alkil) skupinu, halogeno(C1-C4 alkil) skupinu, C3-C6 cikloalkil skupinu, C2-C4 alkenil skupinu, ili C2-C4 alkinil skupinu,
svaki R2a predstavlja C1-C2 alkil skupinu, halogeno(C1-C2 alkil) skupinu gdje halogenu skupinu predstavlja 1 do 5 skupina izabranih iz grupe koju čine fluoro skupina i kloro skupina, C3-C4 cikloalkil skupina, cijano skupina, fluoro skupinu, ili kloro skupinu, i
k predstavlja 0 ili 1.
5. Spoj prema zahtjevu 3 ili njegova farmakološki prikladna sol, gdje
R8a predstavlja C1-C4 alkil skupinu, i
k predstavlja 0.
6. Spoj prema zahtjevu 3 ili njegova farmakološki prikladna sol, gdje
R8a predstavlja etilnu skupinu, i
k predstavlja 0.
7. Spoj prema zahtjevu 1 ili njegova farmakološki prikladna sol, koji je predstavljen sljedećom općom formulom (I-4)
[image]
gdje R3a predstavlja fenil(C1-C2 alkil) skupinu ili supstituiranu fenil(C1-C2 alkil) skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata α1, i
grupa supstituenata α1 predstavlja grupu koju čine C1-C2 alkil skupina, halogeno(C1-C2 alkil) skupina gdje halogenu skupinu(e) predstavlja 1 do 5 skupina izabranih iz grupe koju čine fluoro skupina i kloro skupina, fluoro skupina, i kloro skupina.
8. Spoj prema zahtjevu 7 ili njegova farmakološki prikladna sol, gdje
R3a predstavlja fenilmetil skupinu ili supstituiranu fenilmetil skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata α2, i
grupa supstituenata α2 predstavlja grupu koju čine metil skupina, trifluorometil skupina, i fluoro skupina.
9. Spoj prema zahtjevu 1 ili njegova farmakološki prikladna sol, koji je predstavljen sljedećom općom formulom (I-2)
[image]
10. Spoj prema zahtjevu 1 ili njegova farmakološki prikladna sol, koji je predstavljen sljedećom općom formulom (I-5)
[image]
gdje R8b predstavlja atom vodika, C1-C4 alkil skupinu, (C1-C2 alkoksi)-(C1-C4 alkil) skupinu, halogeno(C1-C4alkil) skupinu, C3-C6 cikloalkil skupinu, C2-C4 alkenil skupinu, ili C2-C4 alkinil skupinu.
11. Spoj prema zahtjevu 10 ili njegova farmakološki prikladna sol, gdje R8b predstavlja C1-C4 alkil skupinu.
12. Spoj prema bilo kojem od zahtjeva 1 do 11 ili njegova farmakološki prikladna sol, gdje R1 predstavlja karboksi skupinu.
13. Spoj prema bilo kojem od zahtjeva 1 do 12 ili njegova farmakološki prikladna sol, gdje svaki od R4, R5, R6, i R7 nezavisno predstavlja atom vodika, C1-C2 alkil skupinu, halogeno(C1-C2 alkil) skupinu gdje halogenu skupinu(e) predstavlja 1 do 5 skupina izabranih iz grupe koju čine fluoro skupina i kloro skupina, fluoro skupina, ili kloro skupina.
14. Spoj prema bilo kojem od zahtjeva 1 do 12 ili njegova farmakološki prikladna sol, gdje svaki od R4, R5, R6, i R7 nezavisno predstavlja atom vodika ili fluoro skupinu.
15. Spoj prema bilo kojem od zahtjeva 1 do 12 ili njegova farmakološki prikladna sol, gdje svaki od R4 i R5 nezavisno predstavlja atom vodika ili fluoro skupinu, i R6 i R7 svaki predstavlja atom vodika.
16. Spoj prema bilo kojem od zahtjeva 1 do 15 ili njegova farmakološki prikladna sol, gdje
B predstavlja naftil skupinu ili supstituiranu naftil skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata α3, i
grupa supstituenata α3 predstavlja grupu koju čine C1-C2 alkil skupina, halogeno(C1-C2 alkil) skupina gdje halogenu skupinu(e) predstavlja 1 do 5 skupina izabranih iz grupe koju čine fluoro skupina i kloro skupina, hidroksi skupina, C1-C2 alkoksi skupina, fluoro skupina, i kloro skupina.
17. Spoj prema bilo kojem od zahtjeva 1 do 15 ili njegova farmakološki prikladna sol, gdje B predstavlja skupinu predstavljenu sljedećom formulom (IIa)
[image]
gdje B1a predstavlja fenil skupinu, supstituiranu fenil skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata α4, 5-eročlanu aromatsku heterocikličku skupinu, ili supstituiranu 5-eročlanu aromatsku heterocikličku skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata α4,
B2a predstavlja fenil skupinu, supstituiranu fenil skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata α5, piridil skupinu, ili supstituiranu piridil skupinu gdje supstituent(i) predstavlja 1 do 3 skupine nezavisno izabrane iz grupe supstituenata α5,
grupa supstituenata α4 predstavlja grupu koju čine C1-C4 alkil skupina, halogeno(C1-C4 alkil) skupina, (C3-C6 cikloalkil)-(C1-C4 alkil) skupina, C3-C6 cikloalkil skupina, C1-C4 alkoksi skupina, formil skupina, (C1-C4 alkil)karbonil skupina, cijano skupina, fluoro skupina, kloro skupina, i bromo skupina, i
grupa supstituenata α5 predstavlja grupu koju čine C1-C4 alkil skupina, halogeno(C1-C4 alkil) skupina, hidroksi skupina, C1-C4 alkoksi skupina, fluoro skupina, kloro skupina, i bromo skupina.
18. Spoj prema bilo kojem od zahtjeva 1 do 15 ili njegova farmakološki prikladna sol, gdje B predstavlja skupinu predstavljenu sljedećom formulom (IIb)
[image]
gdje B1b predstavlja 5-eročlanu aromatsku heterocikličku skupinu koja sadrži dušik ili supstituiranu 5-eročlanu aromatsku heterocikličku skupinu koja sadrži dušik gdje supstituent(i) predstavlja 1 ili 2 skupine nezavisno izabrane iz grupe supstituenata α6,
B2b predstavlja fenil skupinu, supstituiranu fenil skupinu gdje supstituent(i) predstavlja 1 ili 2 skupine nezavisno izabrane iz grupe supstituenata α7, piridil skupinu, ili supstituiranu piridil skupinu gdje supstituent(i) predstavlja 1 ili 2 skupine nezavisno izabrane iz grupe supstituenata α7,
grupa supstituenata α6 predstavlja grupu koju čine C1-C4 alkil skupina, halogeno(C1-C2 alkil) skupina gdje halogenu skupinu(e) predstavlja 1 do 5 skupina izabranih iz grupe koju čine fluoro skupina i kloro skupina, (C3-C4 cikloalkil)-(C1-C2 alkil) skupina, C3-C4 cikloalkil skupina, (C1-C2 alkil)karbonil skupina, cijano skupina, fluoro skupina, i kloro skupina, i
grupa supstituenata α7 predstavlja grupu koju čine C1-C2 alkil skupina, hidroksi skupina, fluoro skupina, i kloro skupina.
19. Spoj prema bilo kojem od zahtjeva 1 do 15 ili njegova farmakološki prikladna sol, gdje B predstavlja skupinu predstavljenu sljedećom formulom (IIc)
[image]
gdje B1c predstavlja skupinu izabranu između sljedećih skupina ili skupinu koja se izabire između sljedećih skupina i supstituirana je pri čemu supstituent predstavlja jednu skupinu nezavisno izabranu iz grupe supstituenata α8
[image]
B2c predstavlja fenil skupinu ili 4-hidroksifenil skupinu, i
grupa supstituenata α8 predstavlja grupu koju čine C1-C4 alkil skupina, halogeno(C1-C2 alkil) skupina gdje halogenu skupinu(e) predstavlja 1 do 5 skupina izabranih iz gruoe koju čine fluoro skupina i kloro skupina, ciklopropil skupina, metilkarbonil skupina, cijano skupina, fluoro skupina, i kloro skupina.
20. Spoj prema bilo kojem od zahtjeva 1 do 15 ili njegova farmakološki prikladna sol, gdje B predstavlja skupinu predstavljenu sljedećom formulom (IId)
[image]
gdje B1d predstavlja skupinu izabranu između sljedećih skupina ili skupinu koja se izabire između sljedećih skupina i supstituirana je pri čemu supstituent predstavlja jednu skupinu izabranu iz grupe supstituenata α9
[image]
i grupa supstituenata α9 predstavlja grupu koju čine metil skupina, etil skupina i kloro skupina.
21. Spoj prema zahtjevu 1 ili njegova farmakološki prikladna sol, koji se izabire iz grupe koju čine
4-{3-[2-(4-hidroksifenil)tiazol-5-il]propanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[2-(4-hidroksifenil)tiazol-5-il]-2-fluoropropanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[3-(4-hidroksifenil)-4-etilizoksazol-5-il]propanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[4-kloro-(4-hidroksifenil)izoksazol-5-il]propanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[4-etil-(4-hidroksifenil)izoksazol-5-il]propanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-3-[(4-hidroksifenil)-4-metilizoksazol-5-il]propanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[2-(4-hidroksifenil)tiazol-5-il]-2,2-difluoropropanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[4-etil-3-(4-hidroksifenil)izoksazol-5-il]-2,2-difluoropropanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[4-etil-5-(4-hidroksifenil)izoksazol-3-il]-2,2-difluoropropanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[4-kloro-5-(4-hidroksifenil)izoksazol-3-il]-2,2-fluoropropanoil}amino-1-etilpirol-3-karboksilna kiselina;
4-{3-[3-(4-hidroksifenil)izoksazol-5-il]-2-fluoropropanoil}amino-1-etilpirol-3-karboksilna kiselina; i
4-{3-[3-(4-hidroksifenil)izoksazol-5-il]-2,2-difluoropropanoil}amino-1-etilpirol-3-karboksilna kiselina.
22. Farmaceutski pripravak koji kao djelatnu tvar sadrži spoj prema bilo kojem od zahtjeva 1 do 21 ili njegovu farmakološki prikladnu sol.
23. Farmaceutski pripravak prema zahtjevu 22, koji je za uporabu u liječenju ili profilaksi hiperlipidemije, dislipidemije, abnormalnosti metabolizma lipida, arterioskleroze ili dijabetesa melitusa tipa II.
24. Farmaceutski pripravak prema zahtjevu 22, koji je za uporabu u liječenju ili profilaksi dislipidemije.
25. Farmaceutski pripravak prema zahtjevu 22, koji je za uporabu u liječenju ili profilaksi abnormalnosti metabolizma lipida.
26. Farmaceutski pripravak prema zahtjevu 22, koji je za uporabu u liječenju ili profilaksi hipertrigliceridemije ili ne-alkoholnog steatohepatitisa.
27. Spoj prema bilo kojem od zahtjeva 1 do 21 ili njegova farmakološki prikladna sol za uporabu u liječenju ili profilaksi hiperlipidemije, dislipidemije, abnormalnosti metabolizma lipida, arterioskleroze ili dijabetesa melitusa tipa II.
28. Spoj prema bilo kojem od zahtjeva 1 do 21 ili njegova farmakološki prikladna sol za uporabu u liječenju ili profilaksi dislipidemije.
29. Spoj prema bilo kojem od zahtjeva 1 do 21 ili njegova farmakološki prikladna sol za uporabu u liječenju ili profilaksi abnormalnosti metabolizma lipida.
30. Spoj prema bilo kojem od zahtjeva 1 do 21 ili njegova farmakološki prikladna sol za uporabu u liječenju ili profilaksi hipertrigliceridemije ili ne-alkoholnog steatohepatitisa.
31. Spoj prema bilo kojem od zahtjeva 1 do 21 ili njegova farmakološki prikladna sol za uporabu kao lijek.
32. Uporaba spoja prema bilo kojem od zahtjeva 1 do 21 ili njegove farmakološki prikladne soli u proizvodnji lijeka za uporabu u liječenju ili profilaksi hiperlipidemije, dislipidemije, abnormalnosti metabolizma lipida, arterioskleroze ili dijabetesa melitusa tipa II.
33. Uporaba spoja prema bilo kojem od zahtjeva 1 do 21 ili njegove farmakološki prikladne soli u proizvodnji lijeka za uporabu u liječenju ili profilaksi dislipidemije.
34. Uporaba spoja prema bilo kojem od zahtjeva 1 do 21 ili njegove farmakološki prikladne soli u proizvodnji lijeka za uporabu u liječenju ili profilaksi abnormalnosti metabolizma lipida.
35. Uporaba spoja prema bilo kojem od zahtjeva 1 do 21 ili njegove farmakološki prikladne soli u proizvodnji lijeka za uporabu u liječenju ili profilaksi hipertrigliceridemije ili ne-alkoholnog steatohepatitisa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008178377 | 2008-07-08 | ||
PCT/JP2009/062331 WO2010004972A1 (ja) | 2008-07-08 | 2009-07-07 | 含窒素芳香族ヘテロシクリル化合物 |
EP09794416.9A EP2308838B1 (en) | 2008-07-08 | 2009-07-07 | Nitrogen-containing aromatic heterocyclyl compound |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160236T1 true HRP20160236T1 (hr) | 2016-05-06 |
Family
ID=41507085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160236TT HRP20160236T1 (hr) | 2008-07-08 | 2016-03-07 | Aromatski heterociklički spoj koji sadrži dušik |
Country Status (25)
Country | Link |
---|---|
US (2) | US8648103B2 (hr) |
EP (1) | EP2308838B1 (hr) |
JP (1) | JP5461398B2 (hr) |
KR (1) | KR20110025742A (hr) |
CN (1) | CN102149680B (hr) |
AU (1) | AU2009269178B2 (hr) |
BR (1) | BRPI0915473A2 (hr) |
CA (1) | CA2730078A1 (hr) |
CO (1) | CO6341610A2 (hr) |
CY (1) | CY1117503T1 (hr) |
DK (1) | DK2308838T3 (hr) |
ES (1) | ES2566529T3 (hr) |
HK (1) | HK1155443A1 (hr) |
HR (1) | HRP20160236T1 (hr) |
HU (1) | HUE028595T2 (hr) |
IL (1) | IL210498A0 (hr) |
MX (1) | MX2011000044A (hr) |
NZ (1) | NZ590790A (hr) |
PL (1) | PL2308838T3 (hr) |
RU (1) | RU2481330C2 (hr) |
SI (1) | SI2308838T1 (hr) |
SM (1) | SMT201600119B (hr) |
TW (1) | TWI435875B (hr) |
WO (1) | WO2010004972A1 (hr) |
ZA (1) | ZA201100183B (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2308838B1 (en) * | 2008-07-08 | 2016-02-17 | Daiichi Sankyo Company, Limited | Nitrogen-containing aromatic heterocyclyl compound |
JP5902029B2 (ja) | 2011-04-28 | 2016-04-13 | 日本たばこ産業株式会社 | アミド化合物およびその医薬用途 |
WO2014065413A1 (ja) * | 2012-10-26 | 2014-05-01 | 日本たばこ産業株式会社 | トリアゾール・イソオキサゾール化合物およびその医薬用途 |
EP2920179A4 (en) * | 2012-11-12 | 2016-03-30 | Victoria Link Ltd | SALT FORMS AND POLYMORPHIC FORMS OF (3R, 4S) -1 - ((4-AMINO-5H-PYRROLO [3,2-D] PYRIMIDIN-7-YL) METHYL) -4- (METHYLTHIOMETHYL) PYRROLIDIN-3-OL (MTDIA) |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
WO2017207983A1 (en) | 2016-05-31 | 2017-12-07 | Kalvista Pharmaceuticals Limited | Pyrazole derivatives as plasma kallikrein inhibitors |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
MD3716952T2 (ro) | 2017-11-29 | 2022-06-30 | Kalvista Pharmaceuticals Ltd | Forme de dozare cuprizând un inhibitor de kalikreină al plasmatică |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060128976A (ko) | 2003-12-29 | 2006-12-14 | 세프라코 아이엔시. | 피롤 및 피라졸 디에이에이오 억제제 |
JP2008518957A (ja) * | 2004-11-04 | 2008-06-05 | メルク エンド カムパニー インコーポレーテッド | ナイアシン受容体作動薬、そのような化合物を含んでいる組成物及び治療方法 |
WO2006052569A1 (en) | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
CN101061092A (zh) | 2004-11-23 | 2007-10-24 | 默克公司 | 烟酸受体激动剂、含有这样化合物的组合物和治疗方法 |
GB0503053D0 (en) | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
GB0505735D0 (en) | 2005-03-21 | 2005-04-27 | Glaxo Group Ltd | Compounds |
JP5113046B2 (ja) | 2005-06-28 | 2013-01-09 | メルク・シャープ・エンド・ドーム・コーポレイション | ナイアシン受容体アゴニスト、このような化合物を含有する組成物及び治療の方法 |
WO2007015744A1 (en) | 2005-07-21 | 2007-02-08 | Incyte Corporation | Disubstituted thienyl compounds and their use as pharmaceuticals |
EP1957524B1 (en) * | 2005-11-18 | 2010-02-17 | Dabur Pharma Limited | Targeted fusion proteins for cancer therapy |
EP1792901A1 (en) | 2005-11-22 | 2007-06-06 | Bayer CropScience S.A. | N-(1-alkyl-2-phenylethyl)-carboxamide derivatives and use thereof as fungicides |
EP1971602A4 (en) * | 2005-12-20 | 2009-11-11 | Merck & Co Inc | AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES |
JP2009526058A (ja) | 2006-02-07 | 2009-07-16 | メルク エンド カムパニー インコーポレーテッド | ナイアシン受容体アゴニスト、該化合物を含有する組成物及び治療の方法 |
JP2009533436A (ja) * | 2006-04-11 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | ナイアシン受容体アゴニスト、かかる化合物を含有する組成物、及び治療法 |
EP2308838B1 (en) * | 2008-07-08 | 2016-02-17 | Daiichi Sankyo Company, Limited | Nitrogen-containing aromatic heterocyclyl compound |
-
2009
- 2009-07-07 EP EP09794416.9A patent/EP2308838B1/en active Active
- 2009-07-07 TW TW098122847A patent/TWI435875B/zh not_active IP Right Cessation
- 2009-07-07 HU HUE09794416A patent/HUE028595T2/en unknown
- 2009-07-07 DK DK09794416.9T patent/DK2308838T3/da active
- 2009-07-07 MX MX2011000044A patent/MX2011000044A/es not_active Application Discontinuation
- 2009-07-07 CN CN200980134944.5A patent/CN102149680B/zh not_active Expired - Fee Related
- 2009-07-07 NZ NZ590790A patent/NZ590790A/xx not_active IP Right Cessation
- 2009-07-07 RU RU2011104223/04A patent/RU2481330C2/ru not_active IP Right Cessation
- 2009-07-07 US US13/001,806 patent/US8648103B2/en not_active Expired - Fee Related
- 2009-07-07 WO PCT/JP2009/062331 patent/WO2010004972A1/ja active Application Filing
- 2009-07-07 SI SI200931400A patent/SI2308838T1/sl unknown
- 2009-07-07 JP JP2010519777A patent/JP5461398B2/ja not_active Expired - Fee Related
- 2009-07-07 ES ES09794416.9T patent/ES2566529T3/es active Active
- 2009-07-07 KR KR1020107025572A patent/KR20110025742A/ko not_active Application Discontinuation
- 2009-07-07 BR BRPI0915473A patent/BRPI0915473A2/pt not_active IP Right Cessation
- 2009-07-07 AU AU2009269178A patent/AU2009269178B2/en not_active Ceased
- 2009-07-07 PL PL09794416T patent/PL2308838T3/pl unknown
- 2009-07-07 CA CA2730078A patent/CA2730078A1/en not_active Abandoned
-
2011
- 2011-01-06 ZA ZA2011/00183A patent/ZA201100183B/en unknown
- 2011-01-06 IL IL210498A patent/IL210498A0/en unknown
- 2011-01-13 CO CO11003214A patent/CO6341610A2/es active IP Right Grant
- 2011-09-12 HK HK11109621.5A patent/HK1155443A1/zh not_active IP Right Cessation
-
2014
- 2014-02-10 US US14/177,000 patent/US9150563B2/en not_active Expired - Fee Related
-
2016
- 2016-03-07 HR HRP20160236TT patent/HRP20160236T1/hr unknown
- 2016-04-22 SM SM201600119T patent/SMT201600119B/it unknown
- 2016-05-13 CY CY20161100405T patent/CY1117503T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160236T1 (hr) | Aromatski heterociklički spoj koji sadrži dušik | |
HRP20210459T1 (hr) | Supstituirani derivati oksopiridina | |
HRP20201171T1 (hr) | Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti | |
JP2019077725A5 (hr) | ||
HRP20170363T1 (hr) | Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret) | |
HRP20172000T1 (hr) | Derivati piperidinil indola i njihova uporaba kao inhibitora komplementnog faktora b | |
JP2011500806A5 (hr) | ||
HRP20130924T1 (hr) | Aminotetrahidropirani kao inhibitori dipeptidil peptidaze-iv za lijeäśenje ili prevenciju dijabetesa | |
SI2834239T1 (en) | Heterobicyclic compounds as inhibitors of beta-lactamase | |
NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
JP2018519323A5 (hr) | ||
JP2016526576A5 (hr) | ||
HRP20100522T1 (hr) | Piridin karboksamidi kao inhibitori 11-beta-hsd1 | |
RU2012125372A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
HRP20161011T1 (hr) | Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2 | |
JP2010508338A5 (hr) | ||
JP2010533160A5 (hr) | ||
JP2014516360A5 (hr) | ||
CA2412968A1 (en) | Substituted pyridines as selective cyclooxygenase-2 inhibitors | |
RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
CA2703125A1 (en) | Pyrazinyl-substituted pyrrolo[2,3-b]pyridines, compositions thereof, and their use in the treatment of cancer | |
JP2016516791A5 (hr) | ||
HRP20160421T1 (hr) | Derivat azola | |
HRP20230789T1 (hr) | Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6 | |
TW200640879A (en) | Amide derivatives |